CLRB

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Cellectar Biosciences Inc

NASDAQ | CLRB

4.79

USD

$0.00

(

0.00%

)

At Close (As of Oct 16, 2025)

$15.86M

Market Cap

-

P/E Ratio

-24.28

EPS

$66.00

52 Week High

$4.11

52 Week Low

HEALTHCARE

Sector

CLRB Chart

Recent Chart
Price Action

CLRB Technicals

Tags:

CLRB Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$292K
Total Revenue $0
Cost Of Revenue $292K
Costof Goods And Services Sold $292K
Operating Income -$52M
Selling General And Administrative $26M
Research And Development $26M
Operating Expenses $52M
Investment Income Net -
Net Interest Income $1.2M
Interest Income $1.2M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $292K
Income Before Tax -$45M
Income Tax Expense $66K
Interest And Debt Expense -
Net Income From Continuing Operations -$45M
Comprehensive Income Net Of Tax -
Ebit -$52M
Ebitda -$51M
Net Income -$45M

Revenue & Profitability

Earnings Performance

CLRB Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $25M
Total Current Assets $24M
Cash And Cash Equivalents At Carrying Value $23M
Cash And Short Term Investments $23M
Inventory -
Current Net Receivables -
Total Non Current Assets $1.2M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $962K
Other Non Current Assets -
Total Liabilities $11M
Total Current Liabilities $9.4M
Current Accounts Payable $4.1M
Deferred Revenue -
Current Debt -
Short Term Debt $84K
Total Non Current Liabilities $1.8M
Capital Lease Obligations $494K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $494K
Other Current Liabilities $5.2M
Other Non Current Liabilities -
Total Shareholder Equity $14M
Treasury Stock -
Retained Earnings -$247M
Common Stock $461
Common Stock Shares Outstanding $1.5M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$48M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $292K
Capital Expenditures $104K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$104K
Cashflow From Financing $61M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$45M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$292K
Total Revenue $0
Cost Of Revenue $292K
Costof Goods And Services Sold $292K
Operating Income -$52M
Selling General And Administrative $26M
Research And Development $26M
Operating Expenses $52M
Investment Income Net -
Net Interest Income $1.2M
Interest Income $1.2M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $292K
Income Before Tax -$45M
Income Tax Expense $66K
Interest And Debt Expense -
Net Income From Continuing Operations -$45M
Comprehensive Income Net Of Tax -
Ebit -$52M
Ebitda -$51M
Net Income -$45M

CLRB News

CLRB Profile

Cellectar Biosciences Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Cellectar Biosciences Inc. is a clinical biopharmaceutical company headquartered in Florham Park, New Jersey, focused on developing innovative cancer therapies through its proprietary phospholipid drug conjugate (PDC) platform. This unique approach enables targeted delivery of therapeutics, enhancing efficacy while minimizing side effects. With a strong pipeline of drug candidates designed to address critical unmet needs in oncology, Cellectar is well-positioned to advance cancer treatment and improve patient outcomes, making it a compelling prospect for institutional investors interested in cutting-edge biopharmaceutical advancements.

VHAI
-20.00%
$0.00
VIVK
-0.33%
$0.29
BURU
+6.18%
$0.35
YYAI
-0.81%
$0.13
CGBS
-39.47%
$0.03
EPWK
+29.85%
$0.09
ADAP
+15.15%
$0.21
BITF
-15.91%
$5.44
PLUG
-3.48%
$3.71
RXRX
-2.94%
$6.59
SCNX
+4.64%
$0.74
MIRA
+57.57%
$2.08
NIO
+0.07%
$6.82
NVDA
+0.32%
$180.42
RGTI
-14.02%
$48.44
WHWK
+19.04%
$2.50
BYND
-11.93%
$0.59
NVTS
+2.37%
$15.52
DNN
-1.05%
$3.13
YDKG
-34.05%
$0.12
AXDX
-61.36%
$0.03
F
-0.72%
$11.67
TLRY
-6.65%
$1.56
IONZ
+18.79%
$3.42
VSEE
-17.98%
$0.49
BBD
+2.04%
$3.26
CAN
-15.05%
$1.66
LGCB
+27.38%
$2.10
DFLI
-31.03%
$1.35
ONDS
-14.10%
$8.16
INTC
-1.17%
$36.71
ACHR
-5.54%
$12.30
GNPX
-41.72%
$0.48
TSLA
-0.86%
$431.37
GDXD
-10.21%
$0.60
MASK
+19.07%
$0.58
LAES
-13.08%
$6.50
BTG
+2.77%
$5.82
AAL
-5.45%
$11.81
RMBL
+60.50%
$3.21
HPE
-11.08%
$22.26
MARA
-7.98%
$21.01
QSI
-1.52%
$2.59
AMD
-0.71%
$236.89
ADD
-25.47%
$0.05
QBTS
-10.16%
$40.23
AUUD
+10.24%
$2.25
NEHC
+9.12%
$3.35
CRML
-6.33%
$21.28
SRM
+53.27%
$10.30
KDLY
+1.29%
$0.79
NAK
-13.06%
$2.29
ABAT
-32.91%
$6.00
SOFI
-4.78%
$26.69
CLF
-1.61%
$13.72
ETHD
+4.49%
$3.95
WOK
+1.21%
$0.05
RGTZ
+28.73%
$11.20
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
IREN
-7.13%
$63.12
TOVX
-43.45%
$0.47
RIG
-1.81%
$3.25
QS
-9.15%
$16.21
WLGS
-5.57%
$0.04
CIFR
-9.12%
$19.11
GPUS
-4.25%
$0.36
SMR
-7.31%
$49.52
ETWO
0.00%
$3.30
SLNH
+2.09%
$4.38
QUBT
-9.06%
$19.30
CLSK
-11.58%
$20.51
SBFM
+10.72%
$2.13
ELBM
-50.95%
$2.31
SOUN
-3.87%
$20.57
ELWS
+74.72%
$6.43
UUUU
-7.22%
$23.18
SNAP
-2.29%
$7.72
APLD
+0.05%
$37.78
MU
+5.84%
$203.16
RR
-6.24%
$5.77
SOND
+47.30%
$1.35
AFMD
-34.94%
$0.18
WULF
-8.14%
$14.21
PLTR
-0.60%
$178.53
RYOJ
+77.41%
$3.85
ASST
-11.49%
$0.84
HIMS
-5.23%
$59.47
DVLT
-11.19%
$1.86
WTO
-87.68%
$0.14
BTBT
-6.77%
$3.78
KEY
-4.43%
$16.94
TMQ
-11.44%
$7.49
PFE
+0.04%
$24.40
RF
-2.92%
$24.01
EOSE
-12.91%
$15.92
OPI
-16.97%
$0.20
HBAN
-3.45%
$15.65
GRAB
-3.03%
$5.74
IONQ
-8.99%
$65.89
VHAI
-20.00%
$0.00
VIVK
-0.33%
$0.29
BURU
+6.18%
$0.35
YYAI
-0.81%
$0.13
CGBS
-39.47%
$0.03
EPWK
+29.85%
$0.09
ADAP
+15.15%
$0.21
BITF
-15.91%
$5.44
PLUG
-3.48%
$3.71
RXRX
-2.94%
$6.59
SCNX
+4.64%
$0.74
MIRA
+57.57%
$2.08
NIO
+0.07%
$6.82
NVDA
+0.32%
$180.42
RGTI
-14.02%
$48.44
WHWK
+19.04%
$2.50
BYND
-11.93%
$0.59
NVTS
+2.37%
$15.52
DNN
-1.05%
$3.13
YDKG
-34.05%
$0.12
AXDX
-61.36%
$0.03
F
-0.72%
$11.67
TLRY
-6.65%
$1.56
IONZ
+18.79%
$3.42
VSEE
-17.98%
$0.49
BBD
+2.04%
$3.26
CAN
-15.05%
$1.66
LGCB
+27.38%
$2.10
DFLI
-31.03%
$1.35
ONDS
-14.10%
$8.16
INTC
-1.17%
$36.71
ACHR
-5.54%
$12.30
GNPX
-41.72%
$0.48
TSLA
-0.86%
$431.37
GDXD
-10.21%
$0.60
MASK
+19.07%
$0.58
LAES
-13.08%
$6.50
BTG
+2.77%
$5.82
AAL
-5.45%
$11.81
RMBL
+60.50%
$3.21
HPE
-11.08%
$22.26
MARA
-7.98%
$21.01
QSI
-1.52%
$2.59
AMD
-0.71%
$236.89
ADD
-25.47%
$0.05
QBTS
-10.16%
$40.23
AUUD
+10.24%
$2.25
NEHC
+9.12%
$3.35
CRML
-6.33%
$21.28
SRM
+53.27%
$10.30
KDLY
+1.29%
$0.79
NAK
-13.06%
$2.29
ABAT
-32.91%
$6.00
SOFI
-4.78%
$26.69
CLF
-1.61%
$13.72
ETHD
+4.49%
$3.95
WOK
+1.21%
$0.05
RGTZ
+28.73%
$11.20
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
IREN
-7.13%
$63.12
TOVX
-43.45%
$0.47
RIG
-1.81%
$3.25
QS
-9.15%
$16.21
WLGS
-5.57%
$0.04
CIFR
-9.12%
$19.11
GPUS
-4.25%
$0.36
SMR
-7.31%
$49.52
ETWO
0.00%
$3.30
SLNH
+2.09%
$4.38
QUBT
-9.06%
$19.30
CLSK
-11.58%
$20.51
SBFM
+10.72%
$2.13
ELBM
-50.95%
$2.31
SOUN
-3.87%
$20.57
ELWS
+74.72%
$6.43
UUUU
-7.22%
$23.18
SNAP
-2.29%
$7.72
APLD
+0.05%
$37.78
MU
+5.84%
$203.16
RR
-6.24%
$5.77
SOND
+47.30%
$1.35
AFMD
-34.94%
$0.18
WULF
-8.14%
$14.21
PLTR
-0.60%
$178.53
RYOJ
+77.41%
$3.85
ASST
-11.49%
$0.84
HIMS
-5.23%
$59.47
DVLT
-11.19%
$1.86
WTO
-87.68%
$0.14
BTBT
-6.77%
$3.78
KEY
-4.43%
$16.94
TMQ
-11.44%
$7.49
PFE
+0.04%
$24.40
RF
-2.92%
$24.01
EOSE
-12.91%
$15.92
OPI
-16.97%
$0.20
HBAN
-3.45%
$15.65
GRAB
-3.03%
$5.74
IONQ
-8.99%
$65.89
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.